SCHEMBL6277631

SCHEMBL6277631

C[C@@H](/C(=N\O)NS(=O)(=O)C(F)(F)F)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 5/20 0.53
PTGS2 P35354 5/20 0.53
MAPT P10636 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 3/20 0.53
CXCR1 P25024 2/20 0.53
CXCR2 P25025 2/20 0.53
CYP3A4 P08684 2/20 0.53
RECQL P46063 1/20 0.53
KDM4E B2RXH2 1/20 0.53
HPGD P15428 1/20 0.53
MAPK1 P28482 1/20 0.53
PMP22 Q01453 1/20 0.53
SLC22A6 Q4U2R8 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CXCL8 P10145 1/20 0.53
THPO P40225 1/20 0.53
HIF1A Q16665 1/20 0.53
CA12 O43570 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7776235 1.00 PTGS1 (0.53) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL6282924 0.86 MAPT (0.58) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL6319806 0.86 MAPT (0.58) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL6277561 0.86 MAPT (0.58) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL1883565 0.73 MAPT (0.64) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL1883564 0.73 MAPT (0.64) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL7488737 0.72 PTGS1 (0.76) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL31441027 0.72 PTGS1 (0.76) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
SCHEMBL23391005 0.72 PTGS1 (0.76) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL679920 0.71 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 PTGS1 29/4885PTGS2 48/4885MAPT 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.